Story
Biotech Firm ADARx Pharmaceuticals Files for Nasdaq IPO
ADARx Pharmaceuticals, a biotechnology company in the late stages of clinical development, has officially filed for a proposed initial public offering on the Nasdaq. According to the filing, the company intends to develop next-generation therapies using small interfering RNA (siRNA) technology.
Filing Details
The company plans to list its shares on the Nasdaq stock exchange under the ticker symbol ADRX. A consortium of major investment banks will serve as underwriters for the proposed offering, including J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, and LifeSci Capital.
The number of shares to be offered and the proposed price range for the IPO have not yet been determined, which is standard for an initial filing.
Company Focus and Pipeline
AdADARx describes its mission as developing therapeutics to treat a wide range of diseases by controlling the expression of specific disease-driving genes. The company's approach centers on highly selective RNA-targeted therapies.
In the filing, ADARx highlighted its current portfolio, which consists of:
- Three clinical-stage programs
- Two advanced preclinical programs
The company stated its goal is to deliver "life-changing treatments for patients with urgent unmet medical needs" by building a leading company in the siRNA therapeutics space.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.